7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Salivary Testosterone and Cortisol as Biomarkers for the Diagnosis of Sarcopenia and Sarcopenic Obesity in Community-Dwelling Older Adults

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Simple Summary

          Sarcopenia (S) and sarcopenic obesity (SO) are diseases that increasingly affect society and constitute an important part of the pathologies that affect elderly due to the high life expectancies of the current population. The search for accessible, inexpensive, and noninvasive biomarkers that can help diagnose these diseases quickly and easily is a new field that deserves an in-depth study. The aim of this study was to find relationships between salivary cortisol (C) and testosterone (T) levels and these pathologies’ appearance in 190 community-dwelling men and women over 65 years old. The results reflect a relationship between salivary T and the age of the participants with differences by sex, and a relationship was found between lower levels of T and a greater presence of S and SO. Despite the significant results obtained, more studies are necessary to determine a potential panel of salivary biomarkers for the study of S and SO.

          Abstract

          Nowadays, the appearance of sarcopenia (S) or sarcopenic obesity (SO) is related to aging. According to the criteria of the European Working Group on Sarcopenia in Older People (EWGSOP), the feasibility of using salivary cortisol and testosterone levels was analyzed as diagnostic biomarkers of S or SO. One hundred and ninety non-institutionalized people aged ≥65 years were studied, independent of the activities of daily living (ADLs) (Barthel > 60), and sociodemographic variables were determined together with criteria for the diagnosis of S and SO including grip force, lower body strength, appendicular skeletal muscle mass, physical performance, total body fat percentage, body mass index (BMI), waist circumference, and triceps skinfold, together with the levels of salivary cortisol and testosterone. Our results reflected that women presented a higher prevalence of S and SO (21.2% and 30.2%, respectively). A significant difference was observed between salivary testosterone levels and the age of the participants with differences by sex. Testosterone values in men with S and SO were significantly lower ( p = 0.043 and p = 0.048, respectively), which suggests a potential use of the biomarker for diagnostic purposes. No significant differences were shown with cortisol values.

          Related collections

          Most cited references74

          • Record: found
          • Abstract: not found
          • Article: not found

          World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

          (2013)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Sarcopenia: revised European consensus on definition and diagnosis

            Abstract Background in 2010, the European Working Group on Sarcopenia in Older People (EWGSOP) published a sarcopenia definition that aimed to foster advances in identifying and caring for people with sarcopenia. In early 2018, the Working Group met again (EWGSOP2) to update the original definition in order to reflect scientific and clinical evidence that has built over the last decade. This paper presents our updated findings. Objectives to increase consistency of research design, clinical diagnoses and ultimately, care for people with sarcopenia. Recommendations sarcopenia is a muscle disease (muscle failure) rooted in adverse muscle changes that accrue across a lifetime; sarcopenia is common among adults of older age but can also occur earlier in life. In this updated consensus paper on sarcopenia, EWGSOP2: (1) focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia; (2) updates the clinical algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation, and severity determination and (3) provides clear cut-off points for measurements of variables that identify and characterise sarcopenia. Conclusions EWGSOP2's updated recommendations aim to increase awareness of sarcopenia and its risk. With these new recommendations, EWGSOP2 calls for healthcare professionals who treat patients at risk for sarcopenia to take actions that will promote early detection and treatment. We also encourage more research in the field of sarcopenia in order to prevent or delay adverse health outcomes that incur a heavy burden for patients and healthcare systems.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Sarcopenia: European consensus on definition and diagnosis

              The European Working Group on Sarcopenia in Older People (EWGSOP) developed a practical clinical definition and consensus diagnostic criteria for age-related sarcopenia. EWGSOP included representatives from four participant organisations, i.e. the European Geriatric Medicine Society, the European Society for Clinical Nutrition and Metabolism, the International Association of Gerontology and Geriatrics—European Region and the International Association of Nutrition and Aging. These organisations endorsed the findings in the final document. The group met and addressed the following questions, using the medical literature to build evidence-based answers: (i) What is sarcopenia? (ii) What parameters define sarcopenia? (iii) What variables reflect these parameters, and what measurement tools and cut-off points can be used? (iv) How does sarcopenia relate to cachexia, frailty and sarcopenic obesity? For the diagnosis of sarcopenia, EWGSOP recommends using the presence of both low muscle mass + low muscle function (strength or performance). EWGSOP variously applies these characteristics to further define conceptual stages as ‘presarcopenia’, ‘sarcopenia’ and ‘severe sarcopenia’. EWGSOP reviewed a wide range of tools that can be used to measure the specific variables of muscle mass, muscle strength and physical performance. Our paper summarises currently available data defining sarcopenia cut-off points by age and gender; suggests an algorithm for sarcopenia case finding in older individuals based on measurements of gait speed, grip strength and muscle mass; and presents a list of suggested primary and secondary outcome domains for research. Once an operational definition of sarcopenia is adopted and included in the mainstream of comprehensive geriatric assessment, the next steps are to define the natural course of sarcopenia and to develop and define effective treatment.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Biology (Basel)
                Biology (Basel)
                biology
                Biology
                MDPI
                2079-7737
                27 January 2021
                February 2021
                : 10
                : 2
                : 93
                Affiliations
                [1 ]Hospital Universitario de La Plana, 12540 Villareal, Spain; angela94dg@ 123456gmail.com
                [2 ]Hospital General Universitari de Castelló, 12004 Castellón, Spain; carlos_ge@ 123456hotmail.es
                [3 ]Department of Preventive Medicine, Hospital Pare Jofré, 46017 Valencia, Spain; Tenias_jma@ 123456gva.es
                [4 ]Food & Health Lab, Institute of Materials Science, University of Valencia, 46980 Valencia, Spain
                [5 ]Joint Research Unit on Endocrinology, Nutrition and Clinical Dietetics, University of Valencia-Health Research Institute La Fe, 46026 Valencia, Spain
                [6 ]Department of Nursing, Faculty of Nursing and Podiatry, University of Valencia, 46001 Valencia, Spain; Julio.Fernandez@ 123456uv.es
                Author notes
                [* ]Correspondence: jose.soriano@ 123456uv.es ; Tel.: +34-963543056
                Author information
                https://orcid.org/0000-0002-2954-6993
                https://orcid.org/0000-0002-5127-6010
                https://orcid.org/0000-0003-2846-1311
                https://orcid.org/0000-0001-5195-5227
                Article
                biology-10-00093
                10.3390/biology10020093
                7911312
                33513704
                75bc013e-ba78-434b-a28d-a7f3061fd13a
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 14 December 2020
                : 24 January 2021
                Categories
                Article

                testosterone,cortisol,community older adults
                testosterone, cortisol, community older adults

                Comments

                Comment on this article